Hot Flashes Are Not Just Uncomfortable. Here Is What They Tell a Cardiologist.

She had twelve hot flashes a day at age 47. Her physician called it normal perimenopause and offered a pamphlet about breathing exercises. What the physician did not say is that women with frequent and severe hot flashes beginning before age 50 show measurably higher rates of endothelial dysfunction and subclinical atherosclerosis in prospective studies. The symptom was also a vascular signal, and the signal was not treated.

The Mechanism

A hot flash is not a flush of warmth. It is a thermoregulatory failure driven by hypothalamic dysregulation, and its cardiovascular footprint is real and measurable.

During the perimenopause transition, declining estrogen narrows the thermoneutral zone in the hypothalamus. This is the range of core body temperature within which the body does not need to actively cool or heat itself. In women with frequent vasomotor symptoms, that zone collapses nearly to zero, meaning trivial temperature shifts trigger full thermoregulatory responses. The hypothalamus then fires the sympathetic nervous system to drive peripheral vasodilation and sweating. The result is the clinical hot flash, but the cardiovascular events embedded within it matter as much as the heat sensation itself.

During each flash, heart rate rises 7 to 15 beats per minute. Peripheral vascular resistance drops acutely as blood is shunted to skin for heat dissipation. Blood pressure fluctuates transiently, with a brief rise from sympathetic activation followed by a dip as cutaneous vasodilation takes hold. Autonomic recovery back to baseline takes 3 to 5 minutes. In a woman experiencing 12 hot flashes per day, that accumulates to roughly 30 to 60 minutes of acute sympathetic cardiovascular stress per 24 hours, before counting nocturnal episodes, which carry additional and distinct consequences.

Nocturnal hot flashes disrupt sleep architecture by fragmenting deep slow-wave sleep and producing arousals. Overnight ambulatory blood pressure monitoring in women with severe nocturnal vasomotor symptoms shows higher mean nocturnal blood pressure and a reduced or absent nocturnal dipping pattern, meaning blood pressure fails to fall the expected 10 to 20 percent during sleep. Non-dipping nocturnal blood pressure is an independent predictor of cardiovascular events across multiple prospective cohorts, separate from and additive to daytime blood pressure levels. These women also show lower overnight heart rate variability, a validated marker of reduced vagal tone and sustained sympathetic drive. Elevated high-sensitivity C-reactive protein levels have been documented in women with frequent vasomotor symptoms, pointing toward a systemic inflammatory state that accompanies the autonomic dysregulation rather than simply reflecting it.

The biological picture is not a woman who is temporarily uncomfortable. It is a woman whose autonomic nervous system is running episodes of sympathetic activation throughout the day and night, whose blood pressure is not dipping during sleep, whose inflammatory markers are elevated, and whose vascular endothelium is absorbing repeated hemodynamic stress. Those are cardiology findings, not gynecological inconveniences.

What the Evidence Shows

The cardiovascular associations with frequent hot flashes are not theoretical or preliminary. They are documented across multiple independent research programs using objective vascular imaging and validated cardiac endpoints.

Rachel Thurston and colleagues at the University of Pittsburgh produced the most rigorous imaging-based evidence. Their work measured brachial artery flow-mediated dilation, the gold-standard clinical test of endothelial function: a brachial artery is occluded for a standardized interval, then released, and the ultrasound-measured dilation of the artery in response to restored blood flow reflects the endothelium’s capacity to produce nitric oxide. Reduced flow-mediated dilation predicts future cardiovascular events. In Thurston’s research, women with more frequent and severe vasomotor symptoms showed significantly lower flow-mediated dilation compared with women who had few or no symptoms, after controlling for age, body mass index, cardiovascular risk factors, and circulating estrogen levels. The endothelial impairment was not explained by the hormonal changes of menopause alone. The vasomotor symptom burden carried independent vascular information.

The same research group documented increased carotid intima-media thickness in women with more severe hot flashes. Carotid intima-media thickness is a structural marker of subclinical atherosclerosis that predates clinical coronary artery disease by years to decades and that independently predicts myocardial infarction and stroke. Higher pulse wave velocity, the measure of aortic stiffness that rises as arterial walls stiffen and lose compliance with early atherosclerosis, was also associated with greater vasomotor symptom burden in Thurston’s analyses.

The Study of Women’s Health Across the Nation, known as SWAN, contributed longitudinal data tracking cardiovascular markers across the menopausal transition in a diverse cohort of several thousand women followed over more than two decades. SWAN data identify a timing distinction that carries clinical weight: women who experience early-onset hot flashes, those beginning before age 50 and before the final menstrual period, carry a distinct and more adverse vascular risk profile compared with women whose hot flashes begin at or after menopause, or who have minimal vasomotor symptoms throughout the transition. Early-onset vasomotor symptoms in SWAN are associated with higher rates of subclinical vascular changes independent of traditional risk factors, suggesting that the hot flashes in these women are reflecting underlying vascular vulnerability rather than simply marking estrogen withdrawal that would affect all women equally.

The Women’s Health Initiative observational data link more frequent and severe vasomotor symptoms to higher rates of cardiovascular events over follow-up periods of more than a decade, providing clinical outcome data to complement the intermediate imaging markers from Thurston’s group and the longitudinal vascular data from SWAN. The threshold that consistently separates the high-risk group in these datasets from women with lower cardiovascular signal is 7 or more moderate-to-severe vasomotor events per day, equivalent to roughly 50 or more per week. Women with 1 or 2 mild hot flashes daily do not carry the same vascular signal as women with 10 to 12 severe daily episodes. Frequency and severity together determine the cardiovascular relevance, not the mere presence of the symptom.

What ties these findings together is a coherent biological pathway. The same hypothalamic-sympathetic dysregulation that produces the hot flash also drives repeated hemodynamic stress on the vascular endothelium. The endothelium, under that chronic repetitive stress, shows reduced nitric oxide availability, inflammatory signaling, and early structural wall changes. Imaging captures those changes years before any clinical event. The clinical event, when it eventually occurs, is not the first sign that something was wrong in the vascular system. It is the late sign. The hot flash was the early sign.

The KNDy Neuron Pathway: What Central Thermoregulation Science Reveals About Vascular Load

The hot flash does not originate in the peripheral vasculature. It originates in the arcuate nucleus of the hypothalamus, and understanding the pathway that generates it clarifies why the cardiovascular footprint extends well beyond the duration of each flush.

The relevant neurons are called KNDy neurons, named for the three neuropeptides they co-express: kisspeptin, neurokinin B, and dynorphin. These neurons are concentrated in the infundibular nucleus of the hypothalamus and regulate the thermoneutral zone through interactions with GnRH neurons and sympathetic outflow pathways. In the presence of estrogen, neurokinin B signaling from KNDy neurons is suppressed, and the thermoneutral zone is maintained at its normal breadth. When estrogen declines, KNDy neurons become hyperactivated, neurokinin B is released in excess, and the thermoneutral zone collapses to near zero — trivial temperature shifts now trigger full thermoregulatory responses via the sympathetic nervous system.

The sympathetic outflow from this centrally generated event is not limited to the skin vasodilation that produces the visible flush. It includes a broader autonomic discharge that elevates heart rate, transiently raises blood pressure, and activates adrenal catecholamine release. Ambulatory cardiac monitoring in women with frequent vasomotor symptoms shows heart rate and blood pressure signatures that persist beyond the duration of the felt flush — the autonomic event outlasts the thermal sensation. In women experiencing ten or twelve hot flashes per day, the cumulative sympathetic burden represents a cardiovascular load that accumulates across the waking hours, on top of the nocturnal blood pressure non-dipping already documented in this population.

The KNDy-neurokinin B pathway has attracted pharmacological attention because it provides a target that does not involve estrogen. Neurokinin 3 receptor antagonists, including fezolinetant, suppress vasomotor symptoms by interrupting KNDy hyperactivation at its central source. The SKYLIGHT 1 and SKYLIGHT 2 trials published in JAMA in 2023 demonstrated reductions in moderate-to-severe vasomotor symptom frequency of approximately 60 percent compared with placebo over 12 weeks. Whether reducing the hot flash burden through this mechanism also reduces the cumulative sympathetic cardiovascular load and improves vascular markers over time is the question requiring longer-term data. The mechanistic case is coherent; the clinical outcome evidence is not yet available. What the pathway clarifies in the present context is that the cardiovascular consequences of frequent hot flashes are driven centrally, not locally, which is why their reach into autonomic balance, blood pressure dynamics, and inflammatory markers is as broad as the imaging studies document. 3 / Early

What to Do This Week

1. Quantify your hot flash burden accurately before your next appointment. Track frequency, severity, and timing for 7 days using a notes app or paper log. Record how many are nocturnal versus daytime, and rate each one on a simple 1-to-3 severity scale. This matters because physicians who dismiss hot flashes as minor often do so without knowing the actual daily count. The clinical threshold where cardiovascular significance is documented is 7 or more moderate-to-severe events per day. If you are at or above that threshold, you need a different conversation than the one you have been having. Give your physician a number.

2. Ask specifically for a cardiovascular risk assessment, not only a symptom conversation. If you are having frequent and severe hot flashes beginning before age 50, request a discussion of blood pressure pattern, endothelial health indicators, and lipid profile framed explicitly in the context of menopausal cardiovascular risk. If your blood pressure has only ever been measured in a daytime clinical setting, ask whether ambulatory blood pressure monitoring makes sense for evaluating your nocturnal dipping pattern. A single office reading at noon does not tell you what your blood pressure is doing at 2am during a hot flash.

3. Have a specific and complete conversation about treatment options, including non-hormonal ones. MHT, when appropriate, reduces hot flash frequency by 70 to 80 percent and eliminates the majority of the sympathetic cardiovascular burden. Transdermal estradiol combined with micronized progesterone carries the most favorable cardiovascular profile among MHT formulations based on available evidence. For women who are not MHT candidates, fezolinetant (Veozah), FDA-approved in 2023, works through neurokinin B receptor antagonism in the hypothalamus and reduces hot flash frequency by 60 to 70 percent without any hormonal mechanism. Paroxetine controlled-release (Brisdelle) is the only SSRI with FDA approval specifically for hot flash reduction and achieves 40 to 60 percent frequency reduction. The goal of treatment in a woman with frequent, severe vasomotor symptoms is not only comfort. It is reduction of the cumulative sympathetic and inflammatory burden on the vascular system.

4. Take nocturnal hot flashes seriously as a separate category with distinct cardiovascular significance. Normal sleep physiology requires sympathetic withdrawal during deep sleep so that blood pressure falls, heart rate slows, and inflammatory repair processes in the vascular endothelium can occur. Nocturnal hot flashes interrupt that recovery window with acute catecholamine events, preventing overnight cardiovascular restoration. If your hot flashes are predominantly or severely nocturnal, say so explicitly when describing your symptoms. Gabapentin has documented efficacy for nocturnal vasomotor symptoms in particular and is a reasonable option to discuss when the overnight pattern is the primary burden, even when daytime symptoms are less severe.

5. Maintain or build aerobic exercise capacity regardless of whether it reduces hot flash frequency. Controlled trials have not found that aerobic exercise substantially reduces the number of hot flashes. They have found that exercise improves cardiovascular fitness, endothelial function, arterial compliance, and autonomic tone independently of vasomotor symptom burden. A woman with ten hot flashes daily who has high cardiorespiratory fitness has a different cardiovascular picture than a woman with the same symptom frequency and low fitness. The cardiovascular risk accumulating from repeated sympathetic activations is partially offset by the vascular protective effects of regular aerobic conditioning. These are not equivalent interventions for the hot flashes themselves, but for the heart, both matter.

The cultural decision to frame hot flashes as discomfort rather than as vascular information has had cardiovascular consequences for women that are not hypothetical. It has directed clinical attention toward symptom management and away from vascular risk assessment at the precise moment in the lifespan when the menopausal transition is actively reshaping cardiovascular risk. A woman told to breathe through her hot flashes is not receiving equivalent clinical care to a man whose physician, seeing the same degree of sympathetic dysregulation, elevated inflammatory markers, and non-dipping nocturnal blood pressure, would order further workup. The frequency and severity of vasomotor symptoms are clinical data about vascular biology. They have always been. The field is catching up to what the physiology was already saying.

Related reading:

• Why Women Wake at 3am
• The MHT Decision Is a Cardiac Decision
• Estrogen Is Not Just a Reproductive Hormone